Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02574663 · ClinicalTrials.gov registry record · Phase 1
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
A Phase 1 study, sponsored by TG Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT02574663: Completed Phase 1 study, sponsored by TG Therapeutics.
NCT02574663 is a Phase 1 study that has completed, run by TG Therapeutics. The registered enrollment target is 66 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02574663, a Phase 1 study, has completed, sponsored by TG Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
This is a Phase 1 multi-center study to assess the safety and efficacy of TGR-1202 as a single agent or in combination with nab-paclitaxel + gemcitabine or with FOLFOX in patients with select relapsed or refractory solid tumors.
Primary Outcome
To determine the incidence of adverse events, any potential abnormal laboratory results and any dose-limiting toxicities.
Interventions
- DRUG TGR-1202
- DRUG nab-paclitaxel + gemcitabine
- DRUG Oxaliplatin + Folinic acid + Fluorouracil
- DRUG Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2015-09-11 |
| Est. Completion | 2018-08 |
| Phase | Phase 1 |
What the finished NCT02574663 record still lists
NCT02574663 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% higher).
The record links to 0 conditions, and to 4 interventions - of which TGR-1202 is the first listed.
NCT02574663 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02574663 about?
NCT02574663 is a clinical study titled "TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors". This is a Phase 1 multi-center study to assess the safety and efficacy of TGR-1202 as a single agent or in combination with nab-paclitaxel + gemcitabine or with FOLFOX in patients with select relapsed or refractory solid tumors.
What is the current status of trial NCT02574663?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2015-09-11. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02574663?
The interventions under investigation include: TGR-1202 (DRUG), nab-paclitaxel + gemcitabine (DRUG), Oxaliplatin + Folinic acid + Fluorouracil (DRUG), Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT02574663?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02574663's enrollment target sits among peer trials
66 786th of 2000 higher than 1,203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI